1-1 of 1 results for subject:Smallpox
Librarians' tools
- Search time
- 0.173 seconds
- Solr query time
- 0.004 seconds
- Search query
- subject:Smallpox
- We searched for
- subject_t:Smallpox OR subject_ses:12852
Primary member
X
Campbell, Anne
Type
House
Session
Year
Department
Member
Primary member
More
Campbell, Anne (1)
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health, what scientific assessments he has carried out of the differences between the Lister and New York strains of the smallpox vaccine.
To ask the Secretary of State for Health, what scientific assessments he has carried out of the differences between the Lister and New York strains of the smallpox vaccine.
Asked by
Anne Campbell
(Labour)
Answered by
Lord Hutton of Furness
(Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Tabled on
15 April 2002
For answer on
14 May 2002
Answered on
14 May 2002
Mrs. Anne Campbell: To ask the Secretary of State for Health what scientific assessments he has carried out of the differences
between the Lister and New York strains of the smallpox vaccine. [50896]
Mr. Hutton: The choice of smallpox vaccine strain took into account expert advice, under the auspices of a specially convened
sub-group of the joint committee on vaccination and immunisation (JCVI).
The advice of the JCVI sub-group was that there was no difference between the two strains on scientific grounds. Vaccines based on
both strains were considered to have been effective in the past.
However, the JCVI sub-group concluded that there is a greater body of evidence to demonstrate the efficacy of the Lister strain
rather than for the New York City Board of Health strain, and that the smallpox vaccine has been challenged in the field more often
by the more severe form of smallpox "variola major" with the strain chosen by the UK Government. The JCVI sub-group also recommended
that using a different strain of vaccine from that used in the United States offered the greatest safeguard if difficulties arose
with the production of either strain ensuring that the alternative strain could act as a fall-back.
Subjects
Standards; Vaccination; Smallpox
Date
14 May 2002
Reference
50896; 385 c617-8W
House
House of Commons